{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T08:53:48Z","timestamp":1794646428733,"version":"4.9.1"},"reference-count":43,"publisher":"American Society of Hematology","issue":"11","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,6,10]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Chimeric antigen receptor (CAR) T-cell products axicabtagene ciloleucel (axi-cel), tisagenlecleucel (tisa-cel), and lisocabtagene maraleucel (liso-cel) are approved for relapsed\/refractory (R\/R) large B-cell lymphoma (LBCL). Emerging evidence indicates that delayed CAR T-cell infusion, including prolonged time from leukapheresis to infusion, known as vein-to-vein time (V2Vt), may adversely impact clinical outcomes. We conducted a systematic literature review (SLR) and meta-analysis to identify differences in V2Vt in patients with R\/R LBCL treated with axi-cel, tisa-cel, or liso-cel. The impact of V2Vt (&amp;lt;28 days vs \u226528 to &amp;lt;40 days vs \u226540 days) on effectiveness and safety outcomes was evaluated in patients treated with axi-cel enrolled in a post-authorization safety study using the Center for International Blood and Marrow Transplant Research data. SLR and meta-analysis showed that patients treated with axi-cel had the shortest median V2Vt (30.6 days) compared with tisa-cel (48.4 days) or liso-cel (35.9 days). Real-world analysis of patients treated with axi-cel demonstrated that V2Vt \u226540 days was associated with significantly lower complete response rate than V2Vt &amp;lt;28 days (odds ratio [OR], 0.61) or \u226528 to &amp;lt;40 days (OR, 0.66) and significantly worse overall survival than V2Vt &amp;lt;28 days (hazard ratio [HR], 1.33) or \u226528 to &amp;lt;40 days (HR, 1.36). Higher prolonged thrombocytopenia rates were observed in patients with axi-cel V2Vt \u226528 to &amp;lt;40 days or \u226540 days compared with &amp;lt;28 days (OR, 1.44 or 1.95, respectively). Together, these results show the impact of V2Vt on patient outcomes with axi-cel therapy and that earlier infusion with CD19-CAR therapies may be beneficial.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024013656","type":"journal-article","created":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T16:56:04Z","timestamp":1738256164000},"page":"2663-2676","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":43,"title":["Impact of vein-to-vein time in patients with R\/R LBCL treated with axicabtagene ciloleucel"],"prefix":"10.1182","volume":"9","author":[{"given":"Frederick L.","family":"Locke","sequence":"first","affiliation":[{"name":"1Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffit Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanya","family":"Siddiqi","sequence":"additional","affiliation":[{"name":"2Department of Hematology\/HCT, City of Hope National Medical Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caron A.","family":"Jacobson","sequence":"additional","affiliation":[{"name":"3Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Nikiforow","sequence":"additional","affiliation":[{"name":"3Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7302-8299","authenticated-orcid":false,"given":"Sairah","family":"Ahmed","sequence":"additional","affiliation":[{"name":"4Department of Lymphoma \u2013 Myeloma, MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0717-4305","authenticated-orcid":false,"given":"David B.","family":"Miklos","sequence":"additional","affiliation":[{"name":"5Department of Medicine - Med\/Blood and Marrow Transplantation, Stanford University School of Medicine, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Lin","sequence":"additional","affiliation":[{"name":"6Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew A.","family":"Lunning","sequence":"additional","affiliation":[{"name":"7Division of Oncology and Hematology, Department of Internal Medicine, Fred & Pamela Buffett Cancer Center, Omaha, NE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian T.","family":"Hill","sequence":"additional","affiliation":[{"name":"8Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8848-8474","authenticated-orcid":false,"given":"Armin","family":"Ghobadi","sequence":"additional","affiliation":[{"name":"9Division of Oncology, Washington University School of Medicine, St. Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen-Huan","family":"Hu","sequence":"additional","affiliation":[{"name":"10Kite, a Gilead Company, Santa Monica, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael T.","family":"Hemmer","sequence":"additional","affiliation":[{"name":"10Kite, a Gilead Company, Santa Monica, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3069-1159","authenticated-orcid":false,"given":"Michael J.","family":"Zoratti","sequence":"additional","affiliation":[{"name":"11RainCity Analytics, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suresh","family":"Vunnum","sequence":"additional","affiliation":[{"name":"10Kite, a Gilead Company, Santa Monica, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Tsang","sequence":"additional","affiliation":[{"name":"10Kite, a Gilead Company, Santa Monica, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clare","family":"Spooner","sequence":"additional","affiliation":[{"name":"10Kite, a Gilead Company, Santa Monica, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry","family":"Smith","sequence":"additional","affiliation":[{"name":"10Kite, a Gilead Company, Santa Monica, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Fu","sequence":"additional","affiliation":[{"name":"10Kite, a Gilead Company, Santa Monica, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anik","family":"Patel","sequence":"additional","affiliation":[{"name":"10Kite, a Gilead Company, Santa Monica, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry","family":"Miao","sequence":"additional","affiliation":[{"name":"10Kite, a Gilead Company, Santa Monica, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shilpa A.","family":"Shahani","sequence":"additional","affiliation":[{"name":"10Kite, a Gilead Company, Santa Monica, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debbie L.","family":"Mirjah","sequence":"additional","affiliation":[{"name":"10Kite, a Gilead Company, Santa Monica, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hairong","family":"Xu","sequence":"additional","affiliation":[{"name":"10Kite, a Gilead Company, Santa Monica, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1579-2293","authenticated-orcid":false,"given":"Marcelo C.","family":"Pasquini","sequence":"additional","affiliation":[{"name":"12Department of Hematology and Oncology \u2013 Medicine, Center for International Blood and Marrow Transplant Research, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,5,28]]},"reference":[{"issue":"1","key":"2025061008165390400_bib1","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"issue":"7","key":"2025061008165390400_bib2","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N Engl J Med"},{"issue":"26","key":"2025061008165390400_bib3","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"2025061008165390400_bib4","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"issue":"10343","key":"2025061008165390400_bib5","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1016\/S0140-6736(22)00662-6","article-title":"Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial","volume":"399","author":"Kamdar","year":"2022","journal-title":"Lancet"},{"key":"2025061008165390400_bib6","volume-title":"YESCARTA\u00ae (axicabtagene ciloleucel) Summary of product characteristics","year":"2021"},{"key":"2025061008165390400_bib7","volume-title":"YESCARTA\u00ae (axicabtagene ciloleucel) Package insert","year":"2022"},{"key":"2025061008165390400_bib8","volume-title":"KYMRIAH\u00ae (tisagenlecleucel) Package insert","year":"2022"},{"key":"2025061008165390400_bib9","volume-title":"KYMRIAH\u00ae (tisagenlecleucel) Summary of product characteristics","year":"2022"},{"key":"2025061008165390400_bib10","volume-title":"BREYANZI\u00ae (lisocabtagene maraleucel) Package insert","year":"2022"},{"key":"2025061008165390400_bib11","volume-title":"BREYANZI\u00ae (lisocabtagene maraleucel) Summary of product characteristics","year":"2023"},{"key":"2025061008165390400_bib12","doi-asserted-by":"crossref","first-page":"913287","DOI":"10.3389\/fmed.2022.913287","article-title":"Toward rapid, widely available autologous CAR-T cell therapy - artificial intelligence and automation enabling the smart manufacturing hospital","volume":"9","author":"Hort","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"2025061008165390400_bib13","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.omtm.2016.12.006","article-title":"Global manufacturing of CAR T cell therapy","volume":"4","author":"Levine","year":"2017","journal-title":"Mol Ther Methods Clin Dev"},{"key":"2025061008165390400_bib14","doi-asserted-by":"crossref","first-page":"573179","DOI":"10.3389\/fimmu.2020.573179","article-title":"Manufacturing and management of CAR T-cell therapy in \u201cCOVID-19's time\u201d: central versus point of care proposals","volume":"11","author":"Ortiz de Landazuri","year":"2020","journal-title":"Front Immunol"},{"issue":"10","key":"2025061008165390400_bib15","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1002\/ajh.26301","article-title":"Efficacy and safety of CD19-directed CAR-T cell therapies in patients with relapsed\/refractory aggressive B-cell lymphomas: observations from the JULIET, ZUMA-1, and TRANSCEND trials","volume":"96","author":"Westin","year":"2021","journal-title":"Am J Hematol"},{"issue":"8","key":"2025061008165390400_bib16","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1080\/10428194.2017.1387905","article-title":"Axicabtagene ciloleucel, a first-in-class CAR T cell therapy for aggressive NHL","volume":"59","author":"Roberts","year":"2018","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"2025061008165390400_bib17","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/j.jcyt.2022.03.013","article-title":"Developing lisocabtagene maraleucel chimeric antigen receptor T-cell manufacturing for improved process, product quality and consistency across CD19(+) hematologic indications","volume":"24","author":"Teoh","year":"2022","journal-title":"Cytotherapy"},{"key":"2025061008165390400_bib18","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.omtm.2019.11.018","article-title":"Optimizing CAR-T cell manufacturing processes during pivotal clinical trials","volume":"16","author":"Tyagarajan","year":"2020","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"suppl 1","key":"2025061008165390400_bib19","doi-asserted-by":"crossref","first-page":"7512","DOI":"10.1182\/blood-2022-155603","article-title":"Real-World Impact of Time from Leukapheresis to Infusion (Vein-to-Vein Time) in Patients with Relapsed or Refractory (r\/r) Large B-Cell Lymphoma (LBCL) Treated with Axicabtagene Ciloleucel.","volume":"140","author":"Locke","year":"2022","journal-title":"Blood"},{"issue":"8","key":"2025061008165390400_bib20","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.jval.2022.02.007","article-title":"Value of reducing wait times for chimeric antigen receptor T-cell treatment: evidence from randomized controlled trial data on tisagenlecleucel for diffuse large B-Cell lymphoma","volume":"25","author":"Chen","year":"2022","journal-title":"Value Health"},{"issue":"10254","key":"2025061008165390400_bib21","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"issue":"7","key":"2025061008165390400_bib22","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa2116596","article-title":"Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma","volume":"386","author":"Bishop","year":"2022","journal-title":"N Engl J Med"},{"issue":"9","key":"2025061008165390400_bib23","doi-asserted-by":"crossref","first-page":"581.e1","DOI":"10.1016\/j.jtct.2022.05.026","article-title":"Real-world evidence of axicabtagene ciloleucel for the treatment of large B cell lymphoma in the United States","volume":"28","author":"Jacobson","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"10","key":"2025061008165390400_bib24","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.jtct.2022.07.011","article-title":"Patterns of use, outcomes, and resource utilization among recipients of commercial axicabtagene ciloleucel and tisagenlecleucel for relapsed\/refractory aggressive B cell lymphomas","volume":"28","author":"Riedell","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"8","key":"2025061008165390400_bib25","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/S1470-2045(22)00339-4","article-title":"Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study","volume":"23","author":"Sehgal","year":"2022","journal-title":"Lancet Oncol"},{"issue":"2","key":"2025061008165390400_bib26","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"issue":"4","key":"2025061008165390400_bib27","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"20","key":"2025061008165390400_bib28","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"issue":"8","key":"2025061008165390400_bib29","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/0021-9681(82)90019-4","article-title":"Corrected group prognostic curves and summary statistics","volume":"35","author":"Chang","year":"1982","journal-title":"J Chronic Dis"},{"issue":"5","key":"2025061008165390400_bib30","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1002\/bimj.4710280508","article-title":"Variance calculations for direct adjusted survival curves, with applications to testing for no treatment effect","volume":"28","author":"Gail","year":"1986","journal-title":"Biometrical J"},{"issue":"6","key":"2025061008165390400_bib31","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/0021-9681(82)90058-3","article-title":"Adjusted survival curve estimation using covariates","volume":"35","author":"Makuch","year":"1982","journal-title":"J Chronic Dis"},{"issue":"16","key":"2025061008165390400_bib32","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"issue":"6","key":"2025061008165390400_bib33","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1080\/10428194.2020.1864349","article-title":"Outcomes and factors impacting use of axicabtagene ciloleucel in patients with relapsed or refractory large B-cell lymphoma: results from an intention-to-treat analysis","volume":"62","author":"Mian","year":"2021","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"2025061008165390400_bib34","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/s41571-022-00607-3","article-title":"Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion","volume":"19","author":"Amini","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"issue":"suppl 1","key":"2025061008165390400_bib35","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/jha2.335","article-title":"Role of bridging therapy during chimeric antigen receptor T cell therapy","volume":"3","author":"Bhaskar","year":"2022","journal-title":"EJHaem"},{"issue":"suppl 1","key":"2025061008165390400_bib36","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1182\/blood-2019-129624","article-title":"Characteristics and outcomes of patients receiving bridging therapy while awaiting manufacture of standard of care axicabtagene ciloleucel CD19 chimeric antigen receptor (CAR) T-cell therapy for relapsed\/refractory large B-cell lymphoma: results from the US Lymphoma CAR-T Consortium","volume":"134","author":"Jain","year":"2019","journal-title":"Blood"},{"issue":"12","key":"2025061008165390400_bib37","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1200\/OP.22.00315","article-title":"Chimeric antigen receptor T-cell therapies: barriers and solutions to access","volume":"18","author":"Mikhael","year":"2022","journal-title":"JCO Oncol Pract"},{"issue":"27","key":"2025061008165390400_bib38","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1200\/JCO.19.02104","article-title":"Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US lymphoma CAR T consortium","volume":"38","author":"Nastoupil","year":"2020","journal-title":"J Clin Oncol"},{"issue":"6","key":"2025061008165390400_bib39","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.3390\/cancers14061501","article-title":"Cytopenia after CAR-T cell therapy-a brief review of a complex problem","volume":"14","author":"Sharma","year":"2022","journal-title":"Cancers"},{"issue":"2","key":"2025061008165390400_bib40","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3324\/haematol.2019.229781","article-title":"Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)","volume":"105","author":"Yakoub-Agha","year":"2020","journal-title":"Haematologica"},{"key":"2025061008165390400_bib41","first-page":"1","article-title":"Infectious complications of CAR T-cell therapy: a clinical update","volume":"8","author":"Stewart","year":"2021","journal-title":"Ther Adv Infect Dis"},{"key":"2025061008165390400_bib42","author":"van de Wiel","year":"2023"},{"issue":"2","key":"2025061008165390400_bib43","doi-asserted-by":"crossref","first-page":"S203","DOI":"10.1016\/j.jtct.2023.12.264","article-title":"Axicabtagene ciloleucel manufacturing experience from launch to present day: a United States perspective","volume":"30","author":"Alquist","year":"2024","journal-title":"Transplant Cell Ther"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/11\/2663\/2376852\/blooda_adv-2024-013656-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/11\/2663\/2376852\/blooda_adv-2024-013656-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T08:17:05Z","timestamp":1749543425000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/11\/2663\/535370\/Impact-of-vein-to-vein-time-in-patients-with-R-R"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,28]]},"references-count":43,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,6,10]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024013656","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,6,10]]},"published":{"date-parts":[[2025,5,28]]}}}